Staged revascularization shows no significant difference versus immediate revascularization for major adverse cardiovascular events in STEMI and MVD patients

This review analyzed data from 5077 patients with ST-segment elevation myocardial infarction and multivessel coronary artery disease. The study compared staged revascularization against immediate revascularization as the primary intervention and comparator. The analysis aimed to determine if delaying revascularization improved clinical outcomes compared to performing the procedure immediately after the initial event. The setting and specific publication details were not reported in the source data. The primary outcome assessed was major adverse cardiovascular events. Secondary outcomes included all-cause mortality, cardiovascular mortality, recurrent myocardial infarction, unplanned ischemia-driven revascularization, stent thrombosis, stroke, major bleeding, acute kidney injury, and heart failure hospitalization.

The primary outcome results showed no significant difference between the two groups. The odds ratio for major adverse cardiovascular events was 1.07 with a 95% CI of 0.76-1.49. This indicates that the risk of the composite endpoint was similar regardless of the timing strategy. For recurrent myocardial infarction, the odds ratio was 1.30 with a 95% CI of 0.80-2.14, which also did not reach statistical significance. Cardiovascular mortality had an odds ratio of 0.76 with a 95% CI of 0.51-1.13. All-cause mortality demonstrated an odds ratio of 0.75 with a 95% CI of 0.54-1.06. None of these specific mortality or morbidity outcomes showed a statistically significant advantage for either approach.

Secondary outcomes were reported as having comparable rates between the two strategies. Stent thrombosis rates were comparable. Stroke rates were comparable. Unplanned ischemia-driven revascularization rates were comparable. Major bleeding rates were comparable. Acute kidney injury rates were comparable. Heart failure hospitalization rates were comparable. Specific absolute numbers, effect sizes, or confidence intervals were not reported for these secondary endpoints. Safety and tolerability findings were not reported in the source data. Serious adverse events were not reported. Discontinuations were not reported.

Methodological limitations significantly impact the interpretation of these findings. Trial sequential analysis indicated insufficient information size to draw definitive conclusions. The certainty of evidence ranged from very low to low. These limitations suggest that the current data may not be robust enough to guide definitive practice changes. The lack of reported funding or conflicts of interest further limits the ability to assess potential bias. The absence of specific setting details makes it difficult to generalize findings to all clinical environments.

Clinical implications suggest that revascularization timing should be individualized pending results from adequately powered trials. The current evidence does not support a clear preference for one strategy over the other based on the primary composite outcome. However, the very low to low certainty of evidence means that clinicians must weigh the specific risks and benefits for each patient. Questions remain unanswered regarding long-term outcomes and specific subgroups that might benefit from one approach over the other. The review highlights the need for further research to resolve uncertainties in managing multivessel disease in the context of STEMI.